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Abstract
Background: This study aimed to synthesize available evidence on the efficacy of dihydroartemisinin-piperaquine
(DHP) in treating uncomplicated Plasmodium vivax malaria in people living in endemic countries.
Methodology and Principal Findings: This is a meta-analysis of randomized controlled trials (RCT). We searched
relevant studies in electronic databases up to May 2013. RCTs comparing efficacy of (DHP) with other artemisinin-
based combination therapy (ACT), non-ACT or placebo were selected. The primary endpoint was efficacy expressed
as PCR-corrected parasitological failure. Efficacy was pooled by hazard ratio (HR) and 95% CI, if studies reported
time-to-event outcomes by the Kaplan-Meier method or data available for calculation of HR Nine RCTs with 14
datasets were included in the quantitative analysis. Overall, most of the studies were of high quality. Only a few
studies compared with the same antimalarial drugs and reported the outcomes of the same follow-up duration, which
created some difficulties in pooling of outcome data. We found the superiority of DHP over chloroquine (CQ) (at day
> 42-63, HR:2.33, 95% CI:1.86-2.93, I2: 0%) or artemether-lumefentrine (AL) (at day 42, HR:2.07, 95% CI:1.38-3.09,
I2: 39%). On the basis of GRADE criteria, further research is likely to have an important impact on our confidence in
the estimate of effect and may change the estimate.
Discussion/Conclusion: Findings document that DHP is more efficacious than CQ and AL in treating uncomplicated
P. vivax malaria. The better safety profile of DHP and the once-daily dosage improves adherence, and its fixed co-
formulation ensures that both drugs (dihydroartemisinin and piperaquine) are taken together. However, DHP is not
active against the hypnozoite stage of P. vivax. DHP has the potential to become an alternative antimalarial drug for
the treatment uncomplicated P. vivax malaria. This should be substantiated by future RCTs with other ACTs.
Additional work is required to establish how best to combine this treatment with appropriate antirelapse therapy
(primaquine or other drugs under development).
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Introduction
According to a recent estimate, Plasmodium vivax accounts
for up to 50% of malaria cases with prevalence rates between
1% and 6% of the population in South and South East Asia,
where the majority of P. vivax malaria occurs. In Central and
South America and Eastern and Southern Africa, it accounts
for 71-81% and 10% of malaria cases, respectively [1–3].
Although P. vivax malaria has a reputation of being a benign
infection, severe and fatal complications also occur [4] such as
maternal anaemia in pregnancy and significant reduction in
mean birthweight [5]. Treatment failure due to resistance to
chloroquine (CQ) in P. vivax was first documented in 1989
among Australians repatriated from Papua New Guinea [3].
Since then, sporadic resistance to CQ has been reported from
other countries including Brazil [6], Ethiopia [7], Myanmar [8]
and Turkey [9], among others. As such, the recent documented
emergence of resistance to CQ in vivax malaria deserves
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paying attention to P. vivax drug sensitivity. Early diagnosis
followed by prompt and effective treatment remains a
cornerstone for the reduction of malaria-related morbidity and
mortality [10]. Along this thread, alternative antimalarial
treatments for P. vivax are needed [11]. In the development of
new antimalarials, dihydroartemisinin-piperaquin (DHP), a
newer co-formulated artemisinin-based combination therapy
(ACT) consisting dihydroartemisinin (DHA) and (bisquinoline)
piperaquine (PPQ), could be considered as an alternative
choice. DHP has recently been added to the list of ACT options
recommended for the treatment of uncomplicated P. falciparum
malaria [12]. The artemisinin (ART) component in DHP (i.e.
DHA) concentrations peak within 25 minutes post-dose, and
DHA is eliminated with a half-life of 30-60 minutes, significantly
shortening the period of exposure of a new infection to a single
drug [13]. The ability of the relatively potent, short-acting ART
derivatives (DHA in our case) to rapidly reduce the parasite
biomass [13,14] results in fewer parasites having to be cleared
by the longer-acting but intrinsically less active partner drug
(PPQ in our case) [15,16]. This subsequently reduces the pool
of parasites from which resistance can emerge [13,14,17].
A previous review of 14 trials solely from the Asian region
has reported that DHP is safe and highly effective for treatment
of uncomplicated falciparum malaria [18]. A Cochrane review
[19] assessing ACTs, including DHP, for treating
uncomplicated malaria was also available. A meta-analysis of
DHP was performed to compare efficacy and safety in treating
P. falciparum per se [20]. Since the publication of these
reviews mainly on uncomplicated falciparum malaria, there has
been a surge of published RCTs undertaken in endemic
countries to compare DHP with other antimalarial agents for
the treatment of vivax malaria. As the epidemiology of malaria
is complex and heterogeneous, with variations over small
areas [21] as well as being age dependent [22], information
from RCTs across geographic regions and all age groups is
valuable.
Taken as a whole, the objective of the present review was to
synthesize the available evidence assessing the efficacy of
DHP in treating uncomplicated P. vivax malaria in people living
in malaria-endemic countries.
Materials and Methods
Search strategy and selection criteria
We conducted a literature search in MEDLINE, EMBASE,
CINHAL, the Cochrane Library and the database of abstract of
Reviews and Effectiveness from January 1989 to May 2013.
For ongoing and unpublished trials, we also looked at the
websites such as http://www.clinicaltrials.gov, http://
www.controlled-trials.com, andhttp://www.nci.nih.gov/
clinicaltrials. Furthermore, we manually searched the reference
sections of the selected studies and relevant reviews to look for
any additional studies which were not found in the initial
search. Searches were limited to English language and those
with human participants. The search terms we used were
malaria, vivax, treatment, dihydroartemisinin, piperaquine,
dihydroartemisinin-piperaquine, Arteken, efficacy, treatment
success, treatment failure, safety, tolerability, resistance. We
determined the inclusion criteria following the PICO format; (1)
Participants (P): those having confirmed P. vivax (either
microscopy or point-of care rapid-onsite diagnostic test for
malaria) mono-infection at enrollment, regardless of age and
pregnancy status; (2) Interventions (I): RCTs in which
participants in one arm should use fixed-dose coformulated
DHP; (3) Comparisons (C): the efficacy of DHP with ACT
antimalarial(s), non-ACT antimalarial(s), or placebo,
(4) Outcomes (O): the proportion of patients with parasitaemia
and provided the effect estimates (or allowed data for
computation of an effect estimate) relative risk (RR), hazards
ratio (HR) or odds ratio (OR) and their corresponding 95%
confidence interval (CI). If a selected study included more than
one comparator, each comparison was regarded as a separate
study. We included studies with participants having mixed
infection (e.g. P. vivax and P. falciparum) for subgroup
analysis. Studies on economic evaluation, mathematical
modeling or pharmacokinetics were not included.
Outcomes
In the present review, outcomes were defined as follows.
Primary outcomes.  1) Polymerase chain reaction (PCR)
confirmed parasitological failure by day 28 after starting
treatment (defined as parasitaemia on any day between day 3
and day 28, irrespective of clinical condition);2) PCR-confirmed
parasitological failure by day 42 after starting treatment
(defined as parasitaemia on any day between day 3 and day
42, irrespective of clinical condition); 3) PCR-confirmed
parasitological failure for more than 42 days after starting
treatment (defined as parasitaemia on any day between day 3
and day 63, irrespective of clinical condition).
Secondary outcomes.  1) Safety outcomes (incidence of
adverse events); 2) Resolution of fever (i.e. time to fever
clearance (FCT)) and 3) time to parasite clearance (PCT).
An adverse event (AE) was defined as any unfavorable,
unintended sign, symptom, syndrome or disease that develops
or worsens with the use of a medicinal product, regardless of
whether it is related to the actual medicinal product. A serious
AE was defined as any untoward medical occurrence that at
any dose; resulted in death; was life threatening; requiring
hospitalization or prolongation of hospitalization; resulted in a
persistent or significant disability or incapacity; or caused a
congenital anomaly or birth defect [23].
Data extraction and quality assessment
Two investigators read all the titles and abstracts collected
through the electronic search and filtered article(s) potentially
eligible for the present study. The two investigators collected
information on baseline characteristics of study design,
participants, characteristics of the experimental drug,
confirmation of P. vivax infection, duration of follow up,
outcomes for each included articles, using a piloted data
abstraction form. Power calculation for the required sample
size was also assessed, if available. If articles contained
information on the same or overlapping study population, we
included the study with the most complete information.
The two investigators independently assessed risk for bias,
following the procedures suggested by the Cochrane Risk of
Meta-Analysis of Randomized Controlled Studies
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Bias tool [24]. The domains were random sequences
generation, allocation concealment, blinding of outcome
assessment and they are classified as ‘low risk’ ‘high risk’ or
‘unclear risk’. Discrepancies were resolved through consensus.
All data were collected on an intention-to-treat (ITT) basis
whenever possible. The two investigators also assessed the
confidence in estimates of treatment effects according to the
Grading of Recommendations Assessments, Development,
and Evaluation (GRADE) approach [25] and made judgments
on risk for bias, precision, consistency, and likelihood of
publication bias. For precision, assessments were made on the
basis of the boundaries of the CI of the summary estimates.
Consistency was judged by visual inspection of forest plot for
similar directions of effect from individual studies and for
narrow ranges of effect size across studies. Publication bias
was assessed by visual inspection of funnel plots.
Data analyses
We performed meta-analysis when 2 or more individual
studies were suitable for pooling on the basis of similarity.
Parasitological efficacy was compared with the rate of
parasitological failure between DHP and the comparator drug.
The parasitological efficacy was pooled by HR and
corresponding 95% CI, if studies reported time-to-event
outcomes by the Kaplan-Meier method or data available for
calculation of HR, using formula described by Parmer [26] and
Tierney [27], as appropriate. Otherwise, we used the
DerSimonian and Laird random effect model when pooling data
and calculated RR and corresponding 95% CI. To test the
robustness of our results, we reanalyzed the effect estimate
using the data from per protocol analysis [35]. We also planned
to reanalyze the effect estimates by excluding individual
studies from the meta-analysis, if data permit.
We assessed heterogeneity by chi-square test and the I2
test. I2 value greater than 50% represented substantial
heterogeneity [24]. Meta-analysis was done using RevMan
Version 5·2 (The Cochrane Collaboration, Nordic Cochrane
Centre, Copenhagen, Denmark) and MetaXL
(www.epigear.com). We summarized the confidence in our
findings by using GRADEProfiler version 3,6 [25].
The protocol of the present study is available in PROSPERO
(CRD: CRD 42013004625) [28]. The methods and findings of
the present review have been reported according to the
preferred reporting items for systematic reviews and meta-
analyses (PRISMA) [29] (Checklist S1).
Results
Figure 1 provides the summary of search and selection of
studies. A total of 213 records were identified, of which a final
count of 16 studies were selected which met the inclusion
criteria [30-45]. The meta-analysis of efficacy studies included
9 studies incorporating 14 datasets [30-38]. Amongst the
studies initially retrieved, the Ashley study [30], provided data
only for mixed infections. Other studies were excluded for a
variety of reasons including: 1) no P. vivax infection detected at
enrollment [39], 2) differentiating information on P. vivax and/or
mixed infections was not provided [40,41], 3) single arm
studies [42,43], 4) only pooled data was available [44] or 5), the
study looked at intermittent preventive treatment (IPT) on a
monthly basis [45].
Baseline characteristics of the included studies are
presented in Table S1. The majority of studies (77%; 7/9) were
performed in Southeast Asian countries. The remaining two
were carried out in Papua New Guinea and Afghanistan,
respectively. All included studies were recent publications
ranging from years 2005-2013 and all were in English. Only
one study was carried out with children under 5-year old [33].
The majority of participants in the primary studies were males,
except a study in Afghanistan [31]. None of the included
studies reported electrocardiogram (ECG) monitoring of
participants during the period of their study.
In the present review, DHP was compared with artesunate-
mefloquine (MAS3) in two trials [30,37], with artemether-
lumefentrine (AL) in two trials [33,36], with artesunate-
amodiaquine (AAQ) in one trial [33], with artemisinin-
naphthoquine (AN) in one trial [38], with CQ plus sulfadoxine-
pyrimethamine (CQ-SP) in one trial [33] and with CQ alone in
two trials [31,35]. All studies assessed DHP, except a recently
published RCT in Indonesia assessed DHP plus primaquine
(PQ) vs AAQ plus PQ for radical treatment of vivax malaria
[38]. Minimum effective plasma concentration of combined CQ-
desethylchloroquine was done in two [33,35] of three studies
where CQ was a comparator. Most of the included studies
were judged to have a ‘low risk of bias’ on the basis of the
random sequences of generation, adequate allocation
concealment and blinding to the laboratory staff. Sample size
calculations were done in 8 studies (88.9%) (Table 1).
1: Effect of intervention stratified by comparator drugs
i): PCR-confirmed parasitaemia at days 28, 42 and at day
>42-63.  DHP versus CQ: At day > 42- 63, two studies (n =
1028) [31,35] showed comparable efficacy (22.7%, 117/516 vs
34.5%, 177/512; RR: 0.51, 95% CI: 0.22-1.16, I2: 75%) in
treating uncomplicated P. vivax malaria (Figure 2). As an
alternative, we did the pooled analysis, using the fixed-effect
model, DHP was better efficacy than CQ (RR: 0.63, 95% CI:
054-0.73, I2: 74%). Of note is the substantial statistical
heterogeneity. The results with HR indicated the higher
cumulative risk of recurrence in the CQ group (HR 2.33, 95%CI
1.86, 2.93, I2: 0%) (Figure 3).
DHP versus AL: At day 42, two studies (n = 837) [33,36]
showed a comparable efficacy between DHP and AL (7.8%,
33/423 vs 28% 116/414, RR: 0.31, 95% CI 0.09-1.12, I2: 93%).
We reanalyzed the data, using the fixed-effect model and DHP
showed better efficacy than AL (RR: 0.27, 95% CI: 0.19-0.36,
I2: 93%); due to substantial heterogeneity, it is not ideal for the
pooled estimate (Figure 2). The results with HR showed the
higher cumulative risk of recurrence in the AL group (HR 2.07,
95%CI 1.86, 3.09, I2: 39%) (Figure 3).
ii): Subgroup analysis.  We planned to stratify analyses by
brand of DHP and age groups. Due to limitations in the data,
we are unable to perform this analysis.
Meta-Analysis of Randomized Controlled Studies
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2: Fever and parasite clearance time in hours
Inadequate data restricted the ability to conduct a pooled
analysis of FCT and PCT. An individual study [33] showed
shorter mean PCT in the DHP group than that of CQ-SP (MD:
1.9, 95% CI: -2.77 to- 1.03), but a comparable mean PCT with
AL (MD: 0.2, 95% CI: -0.77 to 0.31) or ART-SP (MD: 0.1, 95%
CI: -0.55 to 0.75).
3: Adverse events
Due to difficulties in collecting the symptoms reported or
exclusively relating to P. vivax infection, pooled estimates of
AE incidences were not attainable. An individual study [35]
showed that vomiting was less frequent in DHP compared to
CQ (RR: 0.27, 95% CI: 0.11-0.66). DHP related SAE was not
reported in any studies identified for the present review.
Figure 1.  Summary of studies search.  
doi: 10.1371/journal.pone.0078819.g001
Table 1. Risk of bias of the included studies.
Study author Ref. Random sequence generation Allocation concealment Blinding of laboratory staff Sample size calculation
Ashley [30] yes yes yes no
Awab [31] yes yes yes a yes
Hasugian [32] yes yes no yes
Karunajeewa [33] yes unclear yes yes
Pasaribue [34] yes yes NA a yes
Phyo [35] yes yes no yes
Ratclif [36] yes no yes a yes
Smithuis [37] unclear yes yes a yes
Tjitra [38] yes yes yes a yes
Ref.: Reference number; Yes: low risk of bias; No: high risk of bias; unclear: unclear risk of bias;
a. Open label; NA: detailed information not available
doi: 10.1371/journal.pone.0078819.t001
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4: Mixed infections
As a subgroup analysis, two separate studies with mixed
infection (with P. falciparum) showed a comparable efficacy
between DHP and MAS3 [30] (RR: 1, 95% CI: 0.5-2.0) or AL
[35] (RR: 0.83, 95% CI: 0.58-1.18).
5: Sensitivity analyses
For robustness of analysis, we reanalyzed the effect
estimates, using the data from per protocol analysis [35]. At >
42-63 day, DHP and CQ also showed a comparable efficacy
(RR 0.5, 95% CI, 0.22-1.15, I2: 75%). Although we planned to
reanalyze the effect estimates by excluding individual studies
from the meta-analysis, this was not possible due to
inadequate studies. According to the GRADE criteria to
interpret results, further research is likely to have an important
impact on our confidence in the estimate of effect and may
change the estimate (Figure S1).
Discussion
The present study attempted to address the comparative
efficacy and safety of DHP with respect to other antimalarial
agents for the treatment of uncomplicated P. vivax malaria in
patients living in endemic countries, mainly those in Southeast
Asia. Clinical responses to treating malaria patients have an
important role as a decision variable for use by policy makers.
Efficacy
Based on the available data, our findings indicated that
parasitological failure was lower in DHP than that of CQ or AL
This could be explained by the fact that PPQ has the longest
half- life of the drugs (compared to other partner drugs in ACT)
and exposure to therapeutic drug levels over many parasite
cycles is an important determinant of response [15,33]. The
artemisinin component of DHP contributes significantly to the
initial therapeutic response [35], but would not be expected to
affect subsequent relapse or reinfection [31,35,38]. Studies
documented that P. vivax parasite does not cause marked
sequestration [11]. As all stages of asexual development are
present in the peripheral blood, the initial decline in the level of
Figure 2.  Forest plot showing a comparative efficacy of DHP versus comparator drug CQ: Chloroquine, DHP:
dihydroartemisinin-piperaquine, AL: artemether-lumefentrine.  
doi: 10.1371/journal.pone.0078819.g002
Figure 3.  Forest plot showing the cumulative risk of recurrence with P vivax in randomized controlled trials.  CQ:
Chloroquine, DHP: dihydroartemisinin-piperaquine, AL: artemether-lumefentrine.
doi: 10.1371/journal.pone.0078819.g003
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parasitaemia following drug treatment of P. vivax malaria
reflects antimalarial activity and not a combination of
accelerated parasite clearance and sequestration [11,15]. This
was supported by adequate plasma concentration of CQ in
patients of the primary studies. Both CQ and DHP pose long
elimination phases and therefore persistent (and adequate)
blood concentrations, delaying the time to the first relapse. In
areas where CQ sensitive parasites predominate, the
prolonged post-treatment prophylaxis of CQ usually provides a
minimum of 28 days without recurrence.
The relatively shorter mean PCT of DHP compared with CQ-
SP would result in a relatively faster initial symptomatic
response, increasing the confidence of parents/guardians of
children as well as adult patients regarding the new drug. This
is highly important from a clinical viewpoint. Moreover, the SP
component of a drug is potentially important in settings where
P. vivax is dominant and there is high prevalence of G6PD
deficiency such as in certain ethnic groups. For example,
Afghani and Asian patients can suffer significant haemolysis
due to some antimalarials. The rapid development of
resistance to SP when the drug is employed on the national or
regional scale is attributable to the requirement [46].
Of note is that recurrences of P. vivax may consist of a
mixture of relapses from dormant liver stage (hypnozoites),
recrudescences of the erythrocytic infection (due to inadequate
drug levels or resistance), and reinfections acquired from
additional inoculations. It is not possible with current
methodologies to distinguish reliably between these
possibilities [31]. The interpretation of genotyping in the context
of relapsing P. vivax infections is uncertain [47]. Therefore,
genotyping of P. vivax in antimalarial drug trials has not been
carried out as more than half of the parasites that caused the
relapse had a different genotype from those that caused the
primary infection [47,48]. A high rate of mixed-genotype
infections occur even in settings where transmission is low [49],
and true relapses caused by reactivated hypnozoites, cannot
be ruled out or confirmed [47].
Initial parasite clearance was significantly faster after DHP in
the present study and this was consistent with the
pharmacodynamic properties of ACTs observed in P. vivax
[11]. The rapid clearance of parasites in the CQ group, and the
fact that failures were not seen before day 28 in an individual
study [35] suggest that recrudescence associated with CQ
resistance did not contribute significantly to the number of
recurrences. For these reasons, the majority of recurrences
observed in this study are more likely to be relapses [31]. As
such, radical treatment of vivax malaria requires treatment with
PQ. The relapse interval of P. vivax in Southeast Asians has
traditionally been reported to be 6 weeks [50]. There are no
genotyping methods that reliably distinguish relapses from new
infections [47-49], and long-term cultures of P. vivax cannot be
maintained to confine in vitro testing of drugs to assays on
fresh isolates. Therefore, it is difficult to document unequivocal
cases of treatment failure in areas where resistance is
emerging, but any P. vivax infection that occurs within 28 days
after the start of CQ treatment, whether recrudescence,
relapse, or new infection, has grown through residual CQ
concentrations in blood. If these concentrations are adequate,
then, by definition, the infection is resistant [51]. Minimum
effective plasma concentration of combined CQ-
desethylchloroquine was assessed in some of the included
studies, which further supported this claim. The relatively
higher risk of parasitological failure in children under 5 years
treated with DHP [35] was presumably attributed to both from
lower immunity and lower blood PPQ concentrations in this
group [39]. The latter was supported by a population
pharmacokinetic study. Physiological processes do not scale
linearly with body weight, and consequently children need a
higher body weight-based dose than adults to achieve
comparable drug concentration [52]. Therefore, weight
adjusted higher doses may be required in children compared
with adults in order to ensure adequate drug exposure [39].
Mixed infection
Outside Africa, mixed infections of P. falciparum and P. vivax
were common [31,36]. The effects of DHP in suppressing
relapses of P. vivax infection in patients with mixed infections
at baseline have merits. The delay in relapse and reinfections
conferred by DHP gave patients a lengthened period without
symptomatic malaria, allowing for a greater time for
haematological recovery [32,36] and a subsequent reduced
risk of anemia [32,36,38]. It also substantially reduced further
transmission to the mosquito vector. Although such public-
health implications of these benefits need to be confirmed by
longer follow-up [36], it suggests potential programmes.
Of human malaria infections, P. vivax accounts for over half
of all malaria transmitted outside Africa [2]. As almost all RCTs
studies included in the present analysis were carried out in the
Asian region, the current findings should be substantiated with
the studies on efficacy of DHP for the treatment of vivax
malaria in other endemic countries.
For highly effective treatments, it is more appropriate to show
that a treatment is non-inferior or not worse than the standard
treatment, i.e. that the difference in failure rate is not higher
than a pre-specified non-inferiority margin [23]. Along this
thread, published studies have documented that DHP is non-
inferior than any existing antimalarial drugs in treating P.
falciparum infection [18-20]. Due to the small number of
studies, our findings could not prove that DHP is non-inferior to
any existing antimalarial drugs in treating P. vivax infection.
Future studies of well designed with adequate samples
assessing efficacy of DHP in patients having P. vivax infection
are recommended. Studies in endemic countries where P.
vivax is proportionally dominant would be of great value.
Without radical treatment for P. vivax the numbers of patients
who experience one or more, two or more, three or more
relapses are exponential [53]. Additional work is required to
establish how best to combine this treatment with appropriate
antirelapse therapy (PQ or any drug under development),
which is beyond the objective of the current study.
Strengths and limitations of the study
Our review has strengths. Clinically important differences in
the effect of treatment may be obscured if the proportions of
survivors or recovered individuals in the treatment group are
simply compared to that of the control group at a single point in
Meta-Analysis of Randomized Controlled Studies
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e78819
time, such as at the conclusion of the trial. Time-to-event
analysis is, therefore, a potentially more powerful and
informative method of analysis [54,55]. The Kaplan-Meier
method is preferred for statistical analysis of data on drug
efficacy. The advantage of survival analysis is that it takes into
account data on patients who were lost to follow-up or
withdrawn from the study, in particular patients with reinfection
[24]. The present review also showed evidence originated from
the primary studies measured with HR, which is a merit.
Furthermore, if not all, many studies included in the present
review were of high quality.
Despite this, limitations also exist in the present study.
Treatment failure attributable to ‘genuine resistance’ [56] was
not confirmed with measurements of plasma concentrations of
PPQ levels in all studies identified for this review. As the
chemical instability of DHA is a concern [57], it is valuable to
address efficacy of DHP according to pharmaceutical
formulation used for the RCT. However, we are unable to
stratify the analyses by brand of DHP. An unequal
randomization was done in almost all included studies, which
might give unbalanced bias of outcome assessment. On the
other hand, such unequal randomization (e.g., 2:1) could
provide more precise estimates of DHP cure rates and to
provide more patients for the safety database of DHP [42].
Only a few studies compared with the same antimalarial drugs
and reported the outcomes of the same follow-up duration,
which created some difficulties in pooling of outcome data. The
small number of studies with the small sample size in some the
studies means that the possibility of type II statistical errors
cannot be ruled out, as the selected studies were not powered
to test for differences in the outcomes. The present work had
some methodological difficulties with regard to pooling of
results. For example, wide variations in data reporting made it
difficult to compare the incidences of AE. A possible reason is
that these drug-related symptoms could not be differentiated
from malaria symptoms as they are transient and disappear 1-
days after treatment [58]. Three deaths were reported in DHP
group carried out in Thai Myanmar border and overall, these
fatalities were considered as being unlikely to have resulted
from its treatment with DHP [31]. The lack of application of
ECG to measure possible cardiotoxicity in the included studies
is a concern. Although more supporting safety data from RCTs
would be reassuring [30], it is acknowledged that
pharmacovigilance on this drug has not yet been extensive and
some caution is still warranted. An experimental study
suggests that DHP (and AL) neither display a significant
potential proarrhythmic risk nor induce potential Torsade de
pointes (TdP) [59]. We applied GRADE criteria to interpret
results and concluded that further research is likely to have an
important impact on our confidence in the estimate of effect
and may change the estimate.
Conclusion
Findings suggest that DHP is better than CQ and AL in the
treatment of uncomplicated P. vivax malaria. Future RCTs with
other ACTs are recommended. Additional work is required to
establish how best to combine this treatment with appropriate
antirelapse therapy (PQ or other drugs under development).
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